An immunomodulatory vaccine advancing to phase 3 trials highlights the evolving role of immune system recalibration in cancer treatment. From immunotherapy breakthroughs to early-stage scientific ...
Ruxolitinib cream demonstrated favorable safety and efficacy in pediatric atopic dermatitis, highlighting JAK inhibitors' ...
Jonathan Strober, MD, discusses advancements in pediatric myasthenia gravis, emphasizing the need for better treatment standards and effective patient care strategies.
Our top content coverage from the Conference on Retroviruses and Opportunistic Infections (CROI) 2025 highlighted ...
For those and other reasons, targeted oral therapies like Bruton tyrosine kinase inhibitors (BTKis) and the BCL-2 inhibitor ...
Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...
Patients with treatment-naïve chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who received pirtobrutinib (Jaypirca; Eli Lilly) monotherapy showed an 80% reduction in progression ...
Value-based care adoption in employer insurance requires replacing fragmented point solutions with unified, at-risk performance contracts that align vendors, providers, and members around total cost ...
Self-insured employers face regulatory challenges when adopting value-based contracts, requiring careful data governance, standardized metrics, and legal frameworks to align with federal value-based ...
Eric H. Yang, MD, warns that lifetime cardiovascular risk for patients with breast cancer may exceed the general population as life expectancies grow, emphasizing the need for early intervention.
Employers struggle to define value from health care spending amid complexity and misaligned incentives. Achieving measurable outcomes requires transparency, incentive realignment, and gradual, ...
Employers struggle to define value from health care spending amid complexity and misaligned incentives. Achieving measurable outcomes requires transparency, incentive realignment, and gradual, ...